MedTrace Logo

Evaluation of Long-term Efficacy of Treatment With Lamazym

NCT02478840 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-11-20

No results posted yet for this study

Summary

The overall objective is to evaluate the long-term efficacy of Lamazym i.v. treatment in patients with alpha-Mannosidosis previously enrolled in Lamazym trials and currently receiving the treatment according to the AfterCare Program.

Conditions

  • Alpha-Mannosidosis

Interventions

DRUG

Lamazym

recombinant human alpha-mannosidase

Sponsors & Collaborators

  • Zymenex A/S

    lead INDUSTRY

Principal Investigators

  • Allan M Lund, MD · Copenhagen University Hospital, Center for Metabolic Diseases, Department of Clinical Genetics

  • Jens M Fogh, DVM · Zymenex A/S

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02478840 on ClinicalTrials.gov